EP300 and prostate carcinoma: As proof-of-concept, using related bromodomain inhibitor and PROTAC compounds (i.e., GNE-049 and CBPD-409), we demonstrate only p300/CBP degradation to completely extinguish its catalytic activity and trigger a potent growth inhibitory effect in several preclinical prostate cancer models.